ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. BDRX, MAAQ, RANI, MRNS, SNYR, ALLK, INKT, PASG, SCYX, and DYAIShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Biodexa Pharmaceuticals (BDRX), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Synergy CHC (SNYR), Allakos (ALLK), MiNK Therapeutics (INKT), Passage Bio (PASG), SCYNEXIS (SCYX), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Its Competitors Biodexa Pharmaceuticals Mana Capital Acquisition Rani Therapeutics Marinus Pharmaceuticals Synergy CHC Allakos MiNK Therapeutics Passage Bio SCYNEXIS Dyadic International ObsEva (NASDAQ:OBSV) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Which has higher earnings & valuation, OBSV or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than ObsEva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEvaN/AN/A-$58.38M-$0.92N/ABiodexa Pharmaceuticals$470K67.95-$7.32MN/AN/A Which has more volatility and risk, OBSV or BDRX? ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Do insiders and institutionals believe in OBSV or BDRX? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer OBSV or BDRX? In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 0 mentions for ObsEva. Biodexa Pharmaceuticals' average media sentiment score of 1.87 beat ObsEva's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment ObsEva Neutral Biodexa Pharmaceuticals Very Positive Is OBSV or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% Biodexa Pharmaceuticals N/A N/A N/A SummaryBiodexa Pharmaceuticals beats ObsEva on 7 of the 9 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$838.37M$5.54B$9.07BDividend YieldN/A4.84%5.06%4.03%P/E Ratio-0.111.3828.2420.33Price / SalesN/A241.36389.0187.48Price / CashN/A17.6926.2427.98Price / BookN/A6.588.115.50Net Income-$58.38M-$23.83M$3.19B$250.38M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94MN/A-0.1150BDRXBiodexa Pharmaceuticals0.3013 of 5 stars$0.87+0.8%N/AN/A$31.38M$470K0.0020Positive NewsMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+657.3%$30.88MN/A0.001RANIRani Therapeutics2.041 of 5 stars$0.54+0.2%$7.33+1,267.4%-82.6%$30.78M$1.20M-0.54110News CoverageMRNSMarinus Pharmaceuticals2.069 of 5 stars$0.55-0.2%$3.92+613.3%-59.9%$30.32M$30.99M-0.22110SNYRSynergy CHC3.9591 of 5 stars$3.37+4.0%$10.00+196.7%N/A$29.79M$34.83M0.0040ALLKAllakos3.364 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190INKTMiNK Therapeutics1.2195 of 5 stars$7.28+0.6%$37.50+415.5%+472.9%$28.82MN/A-2.8930Trending NewsAnalyst DowngradeGap UpPASGPassage Bio2.5441 of 5 stars$0.43-6.1%$7.50+1,632.1%-97.9%$28.66MN/A-0.42130Stock SplitSCYXSCYNEXIS0.9218 of 5 stars$0.71-3.2%N/A-68.0%$28.54M$3.75M-1.2660Positive NewsDYAIDyadic International3.1676 of 5 stars$0.92-2.6%$6.00+555.4%-33.6%$28.28M$3.49M-4.587Positive NewsGap Down Related Companies and Tools Related Companies Biodexa Pharmaceuticals Alternatives Mana Capital Acquisition Alternatives Rani Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Synergy CHC Alternatives Allakos Alternatives MiNK Therapeutics Alternatives Passage Bio Alternatives SCYNEXIS Alternatives Dyadic International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OBSV Stock Alerts